UBS Group’s Kindred Biosciences, Inc. KIN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q3 | – | Sell |
-64,750
| Closed | -$593K | – | 10702 |
|
|
2021
Q2 | $593K | Sell |
64,750
-17,935
| -22% | -$104K | ﹤0.01% | 4603 |
|
|
2021
Q1 | $411K | Buy |
82,685
+7,149
| +9% | +$34.5K | ﹤0.01% | 5020 |
|
|
2020
Q4 | $325K | Sell |
75,536
-8,700
| -10% | -$35.4K | ﹤0.01% | 4915 |
|
|
2020
Q3 | $361K | Sell |
84,236
-44,649
| -35% | -$187K | ﹤0.01% | 4409 |
|
|
2020
Q2 | $579K | Buy |
128,885
+7,144
| +6% | +$31.9K | ﹤0.01% | 4015 |
|
|
2020
Q1 | $487K | Sell |
121,741
-22,338
| -16% | -$190K | ﹤0.01% | 3981 |
|
|
2019
Q4 | $1.22M | Buy |
144,079
+23,262
| +19% | +$182K | ﹤0.01% | 4019 |
|
|
2019
Q3 | $827K | Buy |
120,817
+39,958
| +49% | +$293K | ﹤0.01% | 4132 |
|
|
2019
Q2 | $674K | Buy |
80,859
+9,600
| +13% | +$82.8K | ﹤0.01% | 4071 |
|
|
2019
Q1 | $653K | Sell |
71,259
-8,651
| -11% | -$87.9K | ﹤0.01% | 3877 |
|
|
2018
Q4 | $875K | Buy |
79,910
+17,764
| +29% | +$224K | ﹤0.01% | 3799 |
|
|
2018
Q3 | $867K | Buy |
62,146
+7,572
| +14% | +$102K | ﹤0.01% | 3969 |
|
|
2018
Q2 | $582K | Buy |
54,574
+8,530
| +19% | +$83.2K | ﹤0.01% | 4200 |
|
|
2018
Q1 | $398K | Sell |
46,044
-1,215
| -3% | -$10.7K | ﹤0.01% | 4350 |
|
|
2017
Q4 | $447K | Sell |
47,259
-153
| -0.3% | -$1.2K | ﹤0.01% | 4369 |
|
|
2017
Q3 | $372K | Sell |
47,412
-19,183
| -29% | -$144K | ﹤0.01% | 4439 |
|
|
2017
Q2 | $572K | Buy |
66,595
+1,378
| +2% | +$9.88K | ﹤0.01% | 4028 |
|
|
2017
Q1 | $460K | Buy |
65,217
+39,411
| +153% | +$247K | ﹤0.01% | 4097 |
|
|
2016
Q4 | $110K | Sell |
25,806
-4,678
| -15% | -$22.6K | ﹤0.01% | 5226 |
|
|
2016
Q3 | $152K | Buy |
30,484
+2,203
| +8% | +$9.31K | ﹤0.01% | 4735 |
|
|
2016
Q2 | $100K | Buy |
28,281
+4,745
| +20% | +$17.4K | ﹤0.01% | 5029 |
|
|
2016
Q1 | $81K | Buy |
23,536
+4,251
| +22% | +$15K | ﹤0.01% | 5135 |
|
|
2015
Q4 | $66K | Buy |
19,285
+4,638
| +32% | +$21.5K | ﹤0.01% | 5577 |
|
|
2015
Q3 | $76K | Buy |
14,647
+8,240
| +129% | +$50.8K | ﹤0.01% | 5464 |
|
|
2015
Q2 | $44K | Buy |
6,407
+2,060
| +47% | +$14.6K | ﹤0.01% | 6110 |
|
|
2015
Q1 | $31K | Sell |
4,347
-2,335
| -35% | -$16.1K | ﹤0.01% | 6520 |
|
|
2014
Q4 | $50K | Buy |
+6,682
| New | +$56.7K | ﹤0.01% | 6488 |
|
Other funds holding KIN
UBS Group's KIN Position: Q3 2021 in Review
UBS Group sold out of Kindred Biosciences, Inc. (KIN) in Q3 2021, closing a stake of 64,750 shares — an estimated $593K sold.
UBS Group first reported a position in KIN in Q4 2014 and held it in 27 quarters. The position peaked at $1.22M in Q4 2019. 1 fund tracked by Wall St. Rank holds KIN as of Q3 2021.
- UBS Group reported no remaining Kindred Biosciences, Inc. position as of Q3 2021 after selling out during the quarter.
- UBS Group sold 64,750 Kindred Biosciences, Inc. shares in Q3 2021, an estimated $593K.
- UBS Group first reported a position in Kindred Biosciences, Inc. in Q4 2014 and held it in 27 quarters.
- UBS Group's Kindred Biosciences, Inc. position peaked at $1.22M in Q4 2019.
- 1 fund tracked by Wall St. Rank held Kindred Biosciences, Inc. as of Q3 2021.
Based on UBS Group's 13F filing for Q3 2021, filed 15 Nov 2021.